Patents Examined by Satyanarayana R. Gudibande
  • Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites
    Patent number: 10307460
    Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting cellular adhesion to RGD binding sites or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: June 4, 2019
    Assignee: Allegro Pharmaceuticals, LLC
    Inventors: Michael John Mackel, John Park
  • Cross-linked poly-E-lysine non-particulate support
    Patent number: 10266652
    Abstract: The invention provides a non-particulate cross-linked poly-?-lysine polymer. The poly-?-lysine and cross linker are linked by amide bonds and may the cross linker has at least two functional groups capable of reacting with an alpha carbon amine of poly-?-lysine. The polymer is suitably insoluble in water and other solvents and is provided in macro form for example a sheet, article or fiber. The macro form polymer is useful in a wide range of applications including wound treatment, as a medical diagnostic comprising a particulate support and a functional material bound or retained by the support and solid phase synthesis of peptides, oligonucleotides, oligosaccharides, immobilisation of species, cell culturing and in chromatographic separation.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: April 23, 2019
    Assignee: SPHERITECH LTD.
    Inventor: Donald A. Wellings
  • Saposin-A derived peptides and uses thereof
    Patent number: 10267799
    Abstract: The invention relates to isolated peptides and chimeric polypeptides derived from Saposin A that have anti-angiogenic activity. These peptides are small, consisting essentially of at least 10 consecutive amino acid residues from the 31st-50th amino acid residue of Saposin A. The invention also relates to the use of these isolated peptides and chimeric polypeptides in compositions for the treatment, prevention, and inhibition of angiogenesis-related diseases and disorders such as cancer and cancer metastasis.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 23, 2019
    Assignee: Children's Medical Center Corporation
    Inventor: Randolph Watnick
  • Cahuitamycins and methods of making and using the same
    Patent number: 10239918
    Abstract: Provided herein are biofilm inhibitors obtained from marine microbial derived natural product extracts from Streptomyces gandocaensis, resulting in biofilm inhibitors, cahuitamycins. Also provided are mutant S. gandocaensis, methods of inhibiting biofilm formation, methods of producing, or increasing the production of, cahuitamycins, methods for synthesizing cahuitamycins, and methods of purifying cahuitamycins.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 26, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: David H. Sherman, Fengan Yu, Chuanwu Xi, Jianfeng Wu, Pamela J. Schultz, Ashootosh Tripathi, Sung Ryeol Park
  • Process for preparing guanidino-functional monomers
    Patent number: 10239828
    Abstract: A process for preparing guanidino-functional, free radically polymerizable compounds comprises (a) combining (1) an amine compound comprising (i) at least one primary aliphatic amino group and (ii) at least one secondary aliphatic amino group, primary aromatic amino group, or secondary aromatic amino group, and (2) a guanylating agent; (b) allowing or inducing reaction of the amine compound and the guanylating agent to form a guanylated amine compound; (c) combining (1) the guanylated amine compound, and (2) a reactive monomer comprising (i) at least one ethylenically unsaturated group and (ii) at least one group that is reactive with an amino group; and (d) allowing or inducing reaction of the guanylated amine compound and the reactive monomer to form a guanidino-functional, free radically polymerizable compound.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: March 26, 2019
    Assignee: 3M Innovative Properties Company
    Inventors: Jerald K. Rasmussen, George W. Griesgraber, James I. Hembre
  • Modulation of synaptic maintenance
    Patent number: 10240156
    Abstract: C1q is shown to be expressed in neurons, where it acts as a signal for synapse elimination. Methods are provided for protecting or treating an individual suffering from adverse effects of synapse loss. These findings have broad implications for a variety of clinical conditions, including treating and preventing neurodegenerative diseases such as Alzheimer's disease.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: March 26, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ben A. Barres, Alexander H. Stephan, Beth A. Stevens
  • Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies
    Patent number: 10231968
    Abstract: The present invention relates generally to a medicinal solution, and more particularly to a medicinal solution which is to be continuously or pulse-delivered for the purpose of treating various ocular diseases, conditions, or maladies, such as keratoconus, infectious keratitis, severe inflammatory conditions, and ocular surface neoplasia. In particular, the medicinal solution comprises the combination of a medication for treating one of the aforenoted or similar diseases, conditions, or maladies, and an anesthetic for rendering the patient comfortable during the treatment procedure.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: March 19, 2019
    Inventors: David R. Hardten, Richard L. Lindstrom
  • Delivery of therapeutic agents by a collagen binding protein
    Patent number: 10213488
    Abstract: Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a PTH/PTHrP receptor agonist are provided. In addition, methods of reducing hair regrowth by administering a composition including a collagen binding polypeptide and a PTH/PTHrP receptor antagonist are provided.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: February 26, 2019
    Assignees: The Board of Trustees of the University of Arkansas, The Kitasato Institute, Montefiore Medical Center
    Inventors: Tulasi Ponnapakkam, Sagaya Theresa Leena Philominathan, Joshua Sakon, Ranjitha Katikaneni, Takaki Koide, Osamu Matsushita, Robert C. Gensure
  • Oligopeptidic compounds and uses thereof
    Patent number: 10213483
    Abstract: Disclosed is A method of treatment of a disorder or condition where it is desirable to inhibit the growth of cells, or a method of treatment which involves cytostatic therapy by administering an oligopeptidic compound to a subject in need thereof. The oligopeptidic compound is capable of interacting with proliferating cell nuclear antigen (PCNA) The compound comprises a PCNA interacting motif which is: which is: [K/R]-[F/Y/W]-[L/I/V/A/M]-[L/I/V/A/M]-[K/R] (SEQ ID NO. 28). The oligopeptidic compound has 9-70 subunits and at least one signal sequence. The signal sequence is a nuclear localization signal sequence and/or a cell penetrating signal sequence. In the compound a PCNA interacting motif is N-terminal to a signal sequence.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: February 26, 2019
    Assignee: APIM THERAPEUTICS AS
    Inventors: Marit Otterlei, Per Arne Aas, Emadoldin Feyzi
  • Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
    Patent number: 10206968
    Abstract: A process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogs and compositions prepared according to the process. The process may comprise lyophilizing a mixture of lanreotide acetate and acetic acid to form a lyophilizate and hydrating the lyophilizate, wherein the lyophilization is performed only once.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: February 19, 2019
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Martin Montes, Thomas Ciaran Loughman, Chantal Roume, Roland Cherif-Cheikh
  • Connective tissue stimulating peptides
    Patent number: 10202419
    Abstract: Novel peptides are described which comprise an amino acid motif selected from the group consisting of “PG”, “GP”, “PI” and “IG” and having up to 10 amino acids upstream and/or downstream of the amino acid motif, wherein “P” in the motif is proline or hydroxyproline and the peptide stimulates the development, maintenance and repair of bone, cartilage and associated connective tissue. The invention further relates to pharmaceutical compositions of these peptides, as well as therapeutic and prophylactic uses of such peptides.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: February 12, 2019
    Assignee: Octane Orthobiologics Inc.
    Inventors: Dennis R. Sindrey, Sydney M. Pugh, Timothy J. N. Smith
  • Stabilized P53 peptides and uses thereof
    Patent number: 10202431
    Abstract: Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: February 12, 2019
    Assignee: Aileron Therapeutics, Inc.
    Inventors: Federico Bernal, Loren D. Walensky, Gregory L. Verdine, Stanley J. Korsmeyer
  • Fusion proteins of collagen-binding domain and parathyroid hormone
    Patent number: 10202434
    Abstract: Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy. Pharmaceutical agents comprising a collagen-binding polypeptide segment linked to a non-peptidyl PTH/PTHrP receptor agonist or antagonist are also presented.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: February 12, 2019
    Assignees: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS, OCHSNER CLINIC FOUNDATION, NATIONAL UNIVERSITY CORPORATION KAGAWA UNIVERSITY
    Inventors: Robert C. Gensure, Joshua Sakon, Osamu Matsushita, Tulasi Ponnapakkam
  • Method of preventing or reducing the progression of prostate cancer
    Patent number: 10183058
    Abstract: The embodiments include methods of preventing or reducing the progression of prostate cancer in mammals susceptible to developing prostate cancer, and to methods of reducing the incidence of clinically detected prostate cancer, using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 22, 2019
    Assignee: NYMOX CORPORATION
    Inventor: Paul Averback
  • Compositions, devices and methods of use thereof for the treatment of cancers
    Patent number: 10159714
    Abstract: The use of GLP-1 receptor agonists, such as glucagon-like peptide-1 (GLP-1) or exenatide, for the treatment of cancer is described. The GLP-1 receptor agonists are typically delivered using an implanted osmotic delivery device that provides for continuous delivery of the GLP-1 receptor agonist for at least one month. Additional beneficial agents, such as anticancer agents, can also be administered.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: December 25, 2018
    Assignee: Intarcia Therapeutics, Inc.
    Inventor: Karling Alice Leung
  • MHC-I restricted epitopes containing non-natural amino acid residues
    Patent number: 10149896
    Abstract: The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: December 11, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Daniel A. Soltis, Lynda G. Tussey
  • ?-AApeptides with potent and broad-spectrum antimicrobial activity
    Patent number: 10144764
    Abstract: The present invention is directed to a novel class of antimicrobial agents called ?-AApeptides. The current invention provides various categories of ?-AApeptides, for example, linear ?-AApeptides, cyclic ?-AApeptides, and lipidated ?-AApeptides. ?-AApeptides of the current invention are designed to exert antimicrobial activity while being stable and non-toxic. ?-AApeptides also do not appear to lead to the development of microbial resistance in treated microorganisms. Thus, the disclosed ?-AApeptides can be used for the treatment of various medical conditions associated with pathogenic microorganisms.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: December 4, 2018
    Assignee: University of South Florida
    Inventors: Jianfeng Cai, Youhong Niu, Haifan Wu, Shruti Padhee
  • High capacity diketopiperazine microparticles and methods
    Patent number: 10130709
    Abstract: Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: November 20, 2018
    Assignee: MannKind Corporation
    Inventors: Marshall Grant, Paul Menkin, Grayson W. Stowell
  • Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
    Patent number: 10130581
    Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: November 20, 2018
    Assignee: MannKind Corporation
    Inventors: Bryan R. Wilson, Marshall Grant
  • Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity
    Patent number: 10100084
    Abstract: Template-fixed ?-hairpin peptidomimetics of the general formulae wherein Z is a chain of 11 ?-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially Cathepsin G or Elastase or Tryptase. These ?-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: October 16, 2018
    Assignees: POLYPHOR LTD., UNIVERSITAT ZURICH
    Inventors: Steven J. Demarco, Kerstin Moehle, Heiko Henze, Odile Sellier, Francoise Jung, Frank Gombert, Daniel Obrecht, Christian Ludin